TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31162128
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention via SMS text messages (every other week or weekly)
Study: 25841624
Drug: Charged Particle
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Charged Particle Therapy (CPT)
Study: 25841624
Drug: Iodine-125 Plaque
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-125 Plaque Therapy
Study: 17309740
Drug: absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: absence of an irrigating solution (control)
Study: 9692126
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of salbutamol inhaled from the MDPI
Study: 9692126
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of salbutamol inhaled from the pMDI + S
Study: 8147091
Drug: R32Tox‐A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: R32Tox‐A vaccine
Study: 28145964
Drug: Laparoscopic-assisted rectus
Normalized name: Sus scrofa rectum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-assisted rectus sheath block (LRSB) with 10 mL of 0.25% levobupivacaine at 4 sites after umbilical wound closure
Study: 24601127
Drug: VUS-guided peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: VUS-guided peripheral intravenous catheter insertion
Study: 16187009
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg daily for 4 weeks
Study: 16187009
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg daily for 4 weeks
Study: 12576946
Drug: MAB-T88 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAB-T88 (300 mg intravenous infusion over 30 mins)
Study: 10593636
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline daily stress
Study: 9363264
Drug: Quinfamide at
Normalized name: quinfamide
DrugBank: Quinfamide (DB12780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinfamide at doses of 4.3 mg/kg b.i.d. in children and 100 mg t.i.d. in adults for one day
Study: 9363264
Drug: Etiamide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiamide at doses of 200 mg t.i.d. in children and 500 mg b.i.d. in adults for three days
Study: 6445816
Drug: 1.5 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 percent solution of erythromycin
Study: 6445816
Drug: 1.5 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 percent solution of erythromycin (continued therapy)
Study: 28319947
Drug: Capsaicin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.75 µg)
Study: 16426289
Drug: Cream product
Normalized name: Oral Cream Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream product preserved with diazolidinyl urea at varying concentrations
Study: 15296364
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (whirlpool, ultrasound, first MPJ mobilizations, calf and hamstring stretching, marble pick-up exercise, cold packs, and electrical stimulation)
Study: 24164587
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic prophylaxis
Study: 24164587
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic antibiotic prophylaxis
Study: 15641864
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 to 8 mg daily for 8 weeks)
Study: 11504166
Drug: Carvedilol plus
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol plus ACE inhibitor (enalapril)
Study: 11504166
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor alone
Study: 9785089
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of macrophages prepared from a blood unit
Study: 7963169
Drug: Glutamine-supplemented parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented parenteral nutrition
Study: 15327343
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (3 blocks of single sessions over one year, 8 to 10 sessions)
Study: 7967359
Drug: Desferrioxamine (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (subcutaneous infusion 50 mg/kg/12 hr)
Study: 7967359
Drug: Desferrioxamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (intravenous infusion 50 mg/kg/6 hr or 100 mg/kg/24 hr)
Study: 7967359
Drug: Desferrioxamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desferrioxamine (both subcutaneous and intravenous)
Study: 31622733
Drug: Durvalumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, 10 mg/kg intravenously every 2 weeks for up to 12 months
Study: 21969495
Drug: P-CAP (perifosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-CAP (perifosine 50 mg orally once daily, days 1 to 21 and CAP 825 mg/m2 orally twice daily, days 1 to 14)
Study: 21969495
Drug: CAP (825
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (825 mg/m2 orally twice daily, days 1 to 14)
Study: 18819175
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (prophylactic agent) with an Active Response Rate (ARR) of 50%
Study: 18819175
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with a Placebo Response Rate (PRR) of 25%
Study: 16918593
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin (INH) administered preprandially using a metered-dose inhaler (MDI) for 4 weeks
Study: 16918593
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GLA) injected subcutaneously at bedtime for 4 weeks
Study: 12600857
Drug: L-5-methyltetrahydrofolate (113
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-methyltetrahydrofolate (113 microg)
Study: 10987607
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous isosorbide-dinitrate (ISDN) 4 mg every 4 min (n = 20)
Study: 10987607
Drug: BiPAP ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP ventilation and standard dose nitrate therapy (n = 20)
Study: 1333903
Drug: L-TAE with
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TAE with Farmorubicin (FARM)
Study: 1333903
Drug: L-TAE with
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TAE with Adriamycin (ADR)
Study: 6711269
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 0.5% mepivacaine with adrenaline (200 mg)
Study: 6711269
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 1% mepivacaine with adrenaline (400 mg)
Study: 6711269
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of 1.5% mepivacaine with adrenaline (600 mg)
Study: 31162191
Drug: XueBiJing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing injection (100 mL, q12 hours)
Study: 31162191
Drug: XueBiJing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: XueBiJing injection
Study: 28750059
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Study: 28750059
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel
Study: 28750059
Drug: RG-TFV gel
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-TFV gel applied before and after receptive anal intercourse (RAI)
Study: 24906790
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU), n=17
Study: 24282626
Drug: Gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (10 mg/kg/day in a single dose for 7 days)
Study: 24282626
Drug: Ofloxacin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (20 mg/kg/day in two divided doses for 7 days)
Study: 21954644
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g i.v. 3 times a day and amikacine 500 mg i.v. 2 times a day (Group 1A)
Study: 21954644
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g i.v. bolus, then permanent infusion 3 g per day and amikacine 15 mg/kg per day once a day (Group 1B)
Study: 19700988
Drug: PCEA (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (0.1% bupivacaine plus hydromorphone 10 mcg/mL at 8 mL/h plus bolus dosing)
Study: 19700988
Drug: IV‐PCA (hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV‐PCA (hydromorphone 2 mcg/kg/h continuous infusion; 2 mcg/kg bolus dose)
Study: 16916874
Drug: 1% chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chloramphenicol and 1% clotrimazole ointment
Study: 16916874
Drug: 1% chloramphenicol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chloramphenicol and placebo ointment
Study: 15675184
Drug: HGF plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF plasmid DNA (three dose/regimens)
Study: 9425843
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole in the night before operation
Study: 8484550
Drug: Continuous supplemental
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous supplemental inspired oxygen by nasal catheters [4 L/min] (Oxygen Group, n = 52)
Study: 3318443
Drug: S-adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosylmethionine (SAMe) 1,200 mg per day
Study: 3318443
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg per day
Study: 26100719
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus text messages timed to medication regimen
Study: 19663111
Drug: Clindamycin-BP 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin-BP 2.5% gel
Study: 12324782
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gluconate and amoxicillin plus clavulanic acid
Study: 12324782
Drug: 0.09% sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% sterile saline solution
Study: 580055
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 2821 (40 mg)
Study: 580055
Drug: Etacrynic acid
Normalized name: Etacrynic acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etacrynic acid (50 mg)
Study: 23964830
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil on alternate days
Study: 23964830
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of statin a day
Study: 23964830
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of tadalafil on alternate days and 10 mg of statin a day
Study: 22668797
Drug: Cilengitide 500
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 500 mg administered intravenously twice weekly
Study: 22668797
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg administered intravenously twice weekly
Study: 11172529
Drug: Biological, psychological,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological, psychological, and psychosocial theories
Study: 24274627
Drug: clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinical management combined with pharmacotherapy
Study: 18693158
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolaevulinate (MAL PDT)
Study: 16725264
Drug: Glutamine granules
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine granules (0.5 g/kg/d for 14 days)
Study: 14609903
Drug: Sucrose and
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose and oral tactile stimulation (with a pacifier or a bottle) and parental holding during immunization
Study: 8993082
Drug: Family-focused psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducational treatment
Study: 6143471
Drug: Beta-adrenoceptor blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor blocker (metoprolol)
Study: 20739445
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement containing (n-3) fatty acids (2.0 g EPA + 0.9 g DHA/d)
Study: 15705052
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g.d(‐1) x 5 d)
Study: 12885709
Drug: Low-phytate bread
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-phytate bread fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Study: 12885709
Drug: Higher-phytate porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-phytate porridge fortified with zinc sulfate (60 mg elemental Zn/kg wheat flour)
Study: 12885709
Drug: Higher-phytate porridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-phytate porridge fortified with zinc oxide (60 mg elemental Zn/kg wheat flour)
Study: 6356145
Drug: Neutrons-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutrons-only therapy
Study: 6356145
Drug: Neutron or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron or mixed-beam therapy
Study: 22731794
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (higher frequency of follow-up)
Study: 22731794
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy group (lower frequency of follow-up)
Study: 19962986
Drug: Earlier-onset puberty
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier-onset puberty (serum testosterone levels >= 2.5 ng/mL at 15 years old, n = 87)
Study: 18396081
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection with EMG assistance
Study: 18396081
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection without EMG assistance
Study: 17121034
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) group with basic therapy and syndrome-differentiation dependent TCM treatment
Study: 17121034
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) group treated with non-steroidal anti-inflammatory drugs and slow-acting antirheumatic drug
Study: 9349927
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1.625 mg/day via pMDI
Study: 9349927
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide 1.60 mg/day via pMDI with integrated spacer
Study: 26766637
Drug: 0.75% povidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% povidone iodine solution for at least 3 minutes
Study: 25219351
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg BID for 3 days followed by topiramate 100 mg BID from days 4 to 10
Study: 25219351
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg QD for 8 days followed by topiramate 96 mg BID from days 9 to 22
Study: 25219351
Drug: Topiramate 96
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 96 mg BID alone for 11 days followed by pioglitazone 30 mg QD and topiramate 96 mg BID from days 12 to 22
Study: 18019884
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (supervised yoga program meeting twice per week for 90 minutes)
Study: 15841103
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement during leuprolide acetate treatment
Study: 10495461
Drug: Bootstrap resampling
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bootstrap resampling method for bias correction in group sequential designs
Study: 7743791
Drug: Normal values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal values of cardiac index (CI) 2.5 < or = CI < or = 3.5 L min‐1 m‐2
Study: 7743791
Drug: Supranormal values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supranormal values of cardiac index (CI > or = 4.5 L min‐1 m‐2)
Study: 17561792
Drug: Human regular
Normalized name: Human regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin (Control)
Study: 15708175
Drug: Regular coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular coffee (80 mg of caffeine)
Study: 11998992
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once-daily
Study: 11998992
Drug: Ipratropium 40
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 40 microg four-times daily
Study: 10551290
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of dexamethasone sodium phosphate
Study: 10551290
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of triamcinolone acetonide
Study: 8703660
Drug: Azapropazone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azapropazone 1200 mg
Study: 21102210
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic continuous infusion device (pain pump) in addition to oral analgesics
Study: 21102210
Drug: Oral analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral analgesics only
Study: 21102210
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic continuous infusion device (pain pump)
Study: 12139207
Drug: Lormetazepam 1
Normalized name: lormetazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam 1 mg tablet
Study: 8187029
Drug: 443c81 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 443c81 (5 ml of a 4 mg/ml solution nebulized) four times daily for 7 days
Study: 8187029
Drug: 443c81 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 443c81 (5 ml of a 4 mg/ml solution nebulized)
Study: 3251339
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous and oral doses of 50 mg of UDCA
Study: 3251339
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of 25, 100, and 300 mg of UDCA
Study: 31153789
Drug: Pilates group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates group 2 (twice a week)
Study: 27804067
Drug: Constant-Activity-Rate (CA)
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-Activity-Rate (CA) infusion
Study: 27804067
Drug: Constant-Flow-Rate (CF)
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant-Flow-Rate (CF) infusion
Study: 27281806
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron and folic acid (IFA) supplements (60 mg Fe and 2800 μg FA)
Study: 27281806
Drug: Weekly multiple
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly multiple micronutrient (MM) supplements (same amount of FA and iron plus other MMs)
Study: 27281806
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (FA) supplements (2800 μg FA)
Study: 20443499
Drug: RT01-based dose-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT01-based dose-volume constraints
Study: 20443499
Drug: CHHiP dose-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHHiP dose-volume constraints
Study: 20443499
Drug: Dose-volume constraints
Normalized name: Constrained Metal (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-volume constraints proposed by other researchers
Study: 18560820
Drug: Lime powder
Normalized name: Lime
DrugBank: Lime (citrus) (DB10635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lime powder solution (Group 1)
Study: 15986401
Drug: Nurse-driven cancer
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-driven cancer care intervention, monthly meetings for 6 months with an oncology nurse, using an interactive computer program.
Study: 10475150
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 microg subcutaneous injections at 18:00 h and 23:00 h)
Study: 10475150
Drug: Saline (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (subcutaneous injections at 18:00 h and 23:00 h)